Please assess the completion status of the following clinical trial:

Trial Title: Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of HIV Type 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Pre-inclusion~Women are eligible for Pre-Entry if they:~* have evidence of HIV infection (confirmed on a second sample);~* present themselves for prenatal care before 26 weeks GA, based on last menstrual period and/or sonogram results;~* intend to stay in the province for at least 18 months after delivery;~* can provide informed consent;~* have given written informed consent to participate in the study;~* intend to carry the pregnancy to term.~Inclusion Criteria:~* all pre-entry criteria;~* date of enrollment: 28 weeks GA, based on last menstrual period and/or sonogram results;~* the following laboratory values within 21 days prior to randomization:~* hemoglobin \> 8.0 g/dL;~* absolute neutrophil count \> 750 cells/mm3;~* SGPT \< 5 x upper limit of normal;~* serum creatinine \< 1.5 mg/dL (women with a serum creatinine \> 1.5 mg/dL must have a measured eight-hour urine creatinine clearance \> 70 mL/min.);~* agreement not to breastfeed.~Exclusion Criteria:~* AIDS according to the Thai Communicable Diseases Control (CDC) classification;~* pre-existing maternal/fetal condition that contraindicates the use of ZDV~* oligohydramnios, unexplained polyhydramnios, fetal hydrops or ascites or other evidence of pre-existing in-utero anemia;~* clinically significant history of intolerance to ZDV treatment resulting in discontinuation of therapy for more than 4 weeks;~* receipt of ZDV during the current pregnancy for any indication, or women who need ZDV for their own health (women are then followed separately);~* receipt of other antiretroviral agents, passive immunotherapy, anti-HIV vaccines, cytolytic agents (usually referred as chemotherapy), radiation therapy, or corticosteroids during this pregnancy except steroids less than 7 (see Zidovudine Investigator's Brochure);~* simultaneous participation in another clinical trial.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Smother-Sinfant)
- 2 (Type: EXPERIMENTAL): Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Smother-Linfant)
- 3 (Type: EXPERIMENTAL): Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Lmother-Sinfant)
- 4 (Type: ACTIVE_COMPARATOR): Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Lmother-Linfant). This study arm was the reference regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).